Thi sissue of Rheumatic Disease Clinics will focus on reproductive health and will include articles on the following: Contraception; infertility - prevention and management; reproductive health screening; biomarkers; use of corticosteroids; and many more exciting articles!
Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It’s estimated that about 300,000 Americans have scleroderma. About one third of those people have the systemic form of scleroderma. Since scleroderma presents with symptoms similar to other autoimmune diseases, diagnosis is difficult. This issue will cover: The Genetic Basis of SSc: Genetics, Epigenetics, Mechanisms of Pathogenesis – linking fibrosis, vasculopathy and immune dysregulation, The Role of Autoantibodies in Diagnosis and Prognosis/survival; Managing Raynaud’s phenomenon and ischemic ulcers, managing SSc Lung Disease, Monitoring for and Managing Pulmonary Arterial Hypertension, and many more!
Edited by Drs. Juergen Braun and Joachim Sieper, this issue of Rheumatic Disease Clinics comprehensively reviews the state of the art of spondyloarthritis (SpA) diagnosis, prognosis, pathogenesis and genetic insights, and treatment. The worldwide burden of SpA now exceeds that of rheumatoid arthritis. General topics covered include inflammatory back pain, pathophysiology, imaging techniques, and therapeutic strategies.
To ensure the best possible clinical outcomes for arthritis patients, it is essential that they be seen early and treated appropriately at the earliest opportunity. Early therapy has proven much more effective than that given late. This issue of Rheumatic Disease Clinics of North America brings the rheumatologist up to date on the latest treatments and interventions in evolving arthritis and established early arthritis. Topics covered include early rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, oligoarthritis, osteoarthritis, and others. Imaging modalities are addressed as well as various contemporary treatments including biologics.
This timely and evocative issue of Rheumatic Disease Clinics explores important current and controversial topics in the treatment of osteoporosis. And it answers some tough questions! Here are some examples. How long do I treat my patient? Is there a place for bone turnover markers? How much Vitamin D should I recommend? Controversies around calcium and Vitamin D are explored regarding the coronary risk and pancreatic issues. Emerging therapies are presented, including sclerostin and oral calcitonin. Long-term safety concerns of antiresporptive therapy (ONJ, atypical fracture, would healing) are explained. The utility and limitations of FRAX are covered, as well as Prolia and the RANKL pathway. An update on glucocorticoid induced OP is given. The reader is also brought up to date on men’s health issues and OP. This is an essential issue for any practicing rheumatologist to stay current in the field.
This issue brings the rheumatologist on the current thinking on treatment of Systemic Lupus Erythematosus, with an eye to the future. Topics covered include B cell biology and related therapies; glutamate receptor biology and its clinical significance in neuropsychiatric SLE; platelet C4d and vascular complications; biomarkers in lupus nephritis; endothelial function and its implications for cardiovascular and renal disease in SLE; changing worldwide epidemiology of SLE and its relationship to environmental, ethnic, and other sociodemographic factors; work loss, disability, quality of life, and compliance in SLE; pediatric lupus; metabolic syndrome and related endocrine abnormalities; the significance of interferon and the consequences of anti-interferon in SLE; and cutaneous lupus and the CLASI instrument.
This issue of the Rheumatic Disease Clinics of North America brings the rheumatologist up to date on the latest breakthroughs in the assessment and treatment of fibromyalgia. Topics covered include fibromyalgia and central sensitization disorders; neurobiology/pathophysiology of fibromyalgia; genetics and socioenvironmental influences; neuroimaging; dysautonomia; sleep; cognition; fibromyalgia in children and adolescents; key symptom domains to be assessed in fibromyalgia; patient-reported outcome measures; nonpharmacologic therapy, including exercise, cognitive behavioral, biofeedback, acupuncture, CAM, and nutrition; pharmacotherapy; and pathophysiology and practical treatment paradigms.